


APC/Fire™ 750 anti-mouse Ly-6G

Catalog # /	1238255 / 25 µg
Size:	1238260 / 100 µg
Clone:	1A8
Isotype:	Rat IgG2a, κ
Immunogen:	Ly-6G transfected EL-4J cell line.
Reactivity:	Mouse
Preparation:	The antibody was purified by affinity chromatography and conjugated with APC/Fire™
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Workshop Number:	750 under optimal conditions.
Concentration:	0.2 mg/ml



C57BL/6 mouse bone marrow cells were stained with Ly-6G (clone 1A8) APC/Fire™ 750 (filled histogram) or rat IgG2a, κ APC/Fire™ 750 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

Application Notes: While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁵. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁵. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4¹⁶.

Additional reported applications (for the relevant formats) include: immunohistochemistry⁹ of frozen sections¹⁰ and paraffin-embedded sections¹¹, and depletion^{4, 12-14}. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for *in vivo* studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).

**Application
References:**

1. Fleming TJ, et al. 1993. *J. Immunol.* 151:2399. (FC)
2. Daley JM, et al. 2008. *J. Leukocyte Biol.* 83:1. (FC)
3. Dietlin TA, et al. 2007. *J. Leukocyte Biol.* 81:1205. (FC)
4. Daley J, et al. 2007. *J. Leukocyte Biol.* doi:10.1189. (Deplete) [PubMed](#)
5. Tadagavadi RK, et al. 2010. *J. Immunol.* 185:4904. [PubMed](#)
6. Sumagin R, et al. 2010. *J. Immunol.* 185:7057. [PubMed](#)
7. Guiducci C, et al. 2010. *J. Exp Med.* 207:2931. [PubMed](#)
8. Fujita M, et al. 2011. *Cancer Res.* 71:2664. [PubMed](#)
9. Van Leeuwen, et al. 2008. *Arterioscler. Thromb. Vasc. Biol.* 28:84. (IHC)
10. Kowanetz M, et al. 2010. *P. Natl. Acad. Sci. USA* 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. *Breast Cancer Res.* 18:35. (IHC)
12. Wojtasiak M, et al. 2010. *J. Gen. Virol.* 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. *J. Exp. Med.* 209:565. (Deplete)
14. Wozniak KL, et al. 2012. *BMC Immunol.* 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. *Eur. J. Immunol.* 39:3538.
16. Ng LG, et al. 2011. *J Invest. Dermatol.* 131:2058. [PubMed](#)
17. Ma C, et al. 2012. *J. Leukoc. Biol.* 92:1199.
18. McCartney-Francis, N, et al. 2014. *J Leukoc. Biol.* 96:917. [PubMed](#)
19. Her Z, et al. 2014. *EMBO Mol. Med.* 7:24. [PubMed](#)

Description: Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.

**Antigen
References:** Fleming TJ, et al. 1993. *J. Immunol.* 151:2399.